中国全科医学2025，Vol.28Issue(20)：2464-2480,17.DOI:10.12114/j.issn.1007-9572.2025.0080
中成药治疗成人社区获得性肺炎临床应用指南(2025版)
Guideline on Treating Adult Community-acquired Pneumonia with Chinese Patent Medicines(2025 Edition)
摘要
Abstract
Community-acquired pneumonia(CAP),one of the common infectious diseases,exhibits increasing morbidity and mortality with age,posing significant clinical challenges.Although Chinese patent medicines(CPMs)demonstrate efficacy in adult CAP treatment,high-quality evidence-based guidelines have been lacking.To address this gap,we organized a multidisciplinary expert panel to develop the Guideline on Treating Community-acquired Pneumonia with Chinese Patent Medicines,adhering to the principles of evidence-based,consensus-supplemented,and experience-referred and following standardized clinical practice guideline development procedures.Through literature review and Delphi questionnaires,six clinical questions were identified.Systematic evidence retrieval and synthesis of the best available evidence were conducted,integrating factors such as evidence quality,patient preferences,value orientations,and resource allocation.After two rounds of Delphi surveys and expert consensus meetings,the guideline was finalized and published in 2023 in Pharmacological Research.This updated edition systematically incorporates recent evidence,adds pharmacoeconomic evaluations and recommendation rationales,and presents 14 recommendations covering nine CPMs,covers 9 kinds of traditional Chinese patent medicines.The guideline has been restructured according to the first edition of reporting checklist for Chinese patent medicine guidelines(RIGHT for CPM)to enhance clinical applicability,accessibility,and operationalizability,thereby promoting the rational use of CPMs in adult CAP treatment.关键词
社区获得性肺炎/中成药/治疗/成人/指南Key words
Community-acquired pneumonia/Chinese patent medicines/Therapy/Adult/Guideline分类
临床医学引用本文复制引用
杨江,李素云,王明航,代表编制组,李建生,陈耀龙,刘辉国,王建新,喻佳洁,李慧茹,肖琼华,谢洋..中成药治疗成人社区获得性肺炎临床应用指南(2025版)[J].中国全科医学,2025,28(20):2464-2480,17.基金项目
国家重点研发计划"中医药现代化研究"重点专项(2023YFC3502602) （2023YFC3502602）
国家中医药管理局中成药治疗优势病种标准化项目(SATCM-2015-BZ402-407) （SATCM-2015-BZ402-407）
国家自然科学基金面上项目(82474483) （82474483）
